Therapeutic Solutions International, Inc. (TSOI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Therapeutic Solutions International, Inc. (TSOI) trades at $0.0001 with AI Score 54/100 (Grade B). Therapeutic Solutions International, Inc. (TSOI) specializes in immune system modulation, developing agents for diverse serious conditions including cancers, neurological disorders, and lung pathologies. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for TSOI: TSOI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TSOI against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
TSOI: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Therapeutic Solutions International, Inc. (TSOI) Healthcare & Pipeline Overview
Therapeutic Solutions International, Inc. (TSOI) focuses on immune system modulation, developing agents for diverse serious conditions like cancers, neurological disorders, and lung pathologies. The company offers patented QuadraMune and a range of nutraceuticals, while actively advancing therapeutics for chronic traumatic encephalopathy, traumatic brain injury, and lung diseases within the biotechnology sector.
What Is the Investment Thesis for TSOI?
Therapeutic Solutions International, Inc. (TSOI) operates within the biotechnology sector, focusing on immune system modulation to address a broad spectrum of serious conditions, from cancers to neurological disorders and lung pathologies. A key value driver for TSOI is its diversified product strategy, encompassing both a patented nutraceutical line, exemplified by QuadraMune, and an active pipeline of advanced therapeutics targeting chronic traumatic encephalopathy, traumatic brain injury, and lung diseases. The company's intellectual property portfolio, particularly around its cellular therapy technologies and patented formulations like QuadraMune, represents a potential strength, offering a competitive edge in specialized markets. Financially, TSOI reported a gross margin of 62.9%, indicating efficiency in its cost of goods sold, although it currently operates with a significant negative profit margin of -2191.9%. Growth catalysts include the ongoing development and potential future clinical trial successes of its advanced therapeutic candidates, as well as the continued market penetration and expansion of its nutraceutical offerings. However, as an OTC Other listed company, TSOI faces inherent risks, including limited liquidity, potential regulatory hurdles, and the necessity to secure future financing for its research and development initiatives. Investors should closely monitor progress in clinical trials and any announcements regarding financing activities to assess the company's trajectory.
Based on FMP financials and quantitative analysis
TSOI Key Highlights
Market capitalization of $0.00 billion, reflecting its current valuation.
- Profit margin of -2191.9%, indicating significant unprofitability.
- Gross margin of 62.9%, demonstrating efficiency in direct production costs.
- Beta of 0.48, suggesting lower volatility compared to the broader market.
- Operates with 3 employees, indicating a lean organizational structure.
Who Are TSOI's Competitors?
TSOI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.21% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TSOI's Key Strengths?
Patented QuadraMune formulation with a specific immune-modulatory mechanism.
- Diverse portfolio of nutraceuticals and a pipeline of advanced therapeutics.
- Intellectual property surrounding cellular therapy technologies provides a competitive edge.
- Gross margin of 62.9% indicates efficient cost management for products sold.
What Are TSOI's Weaknesses?
Significant negative profit margin of -2191.9% indicates unprofitability.
- Small employee base of 3, potentially limiting R&D and operational scale.
- OTC Other listing implies limited liquidity and potential difficulties in capital raising.
- Disclosure status is unknown, which can deter institutional investors.
What Could Drive TSOI Stock Higher?
TSOI catalyst: Development of advanced therapeutics for chronic traumatic encephalopathy, traumatic brain injury, and various lung diseases.
- Commercialization and market penetration efforts for patented QuadraMune and other specialized nutraceuticals.
- Potential announcements regarding clinical trial results for pipeline therapeutic candidates.
- Future financing activities to support ongoing research and development and operational expansion.
What Are the Key Risks for TSOI?
Financial-distress signal — its Altman Z-Score of -12.03 sits in the distress zone (elevated bankruptcy risk).
- Significant negative profit margin of -2191.9%, indicating current unprofitability.
- Inherent risks associated with limited liquidity and regulatory hurdles due to the OTC Other listing.
- Clinical trial failures or delays for advanced therapeutic candidates, impacting future revenue potential.
- Challenges in securing adequate future financing to sustain research, development, and operational activities.
- Intense competition within both the biotechnology and nutraceutical sectors, potentially limiting market share.
What Are the Growth Opportunities for TSOI?
- Expansion of Patented QuadraMune Applications: Therapeutic Solutions International, Inc.'s patented QuadraMune blend, engineered to amplify natural killer cell activity and foster healthy cytokine production, presents a significant growth avenue. The current market for immune-boosting supplements and natural health products is substantial and continues to expand, driven by increasing consumer awareness of immune health. By exploring new indications or expanding its market reach through strategic partnerships and enhanced distribution channels, TSOI could significantly increase revenue from this flagship product. The unique synergistic blend offers a differentiated product in a crowded market, potentially allowing for premium pricing and sustained growth over the next 3-5 years as consumers prioritize preventative health measures.
- Development of Advanced Therapeutics for Unmet Needs: The company's active development of advanced therapeutics for chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), and lung diseases represents a high-potential growth driver. These conditions currently have limited effective treatments, indicating a substantial unmet medical need and a large potential market size. Successful progression through clinical trials and eventual regulatory approval for even one of these therapeutic candidates could unlock significant revenue streams and dramatically increase the company's valuation. The timeline for such development is typically long-term, spanning 5-10 years, but the potential rewards in these critical therapeutic areas are considerable.
- Penetration of the Nutraceutical Market with Diverse Offerings: Beyond QuadraMune, TSOI's extensive range of nutraceuticals, including ProJuvenol, various pterostilbene formulations (NanoStilbene, DermalStilbene, IsoStilbene, NeuroStilbene), and Nano Cannabidiol products, positions the company to capitalize on the robust and expanding global nutraceutical market. This market is projected to continue its growth trajectory, driven by an aging population and increasing health consciousness. By effectively marketing these specialized blends and leveraging their unique delivery mechanisms, such as nanotechnology, TSOI can capture a larger share of this consumer-driven health segment. This opportunity offers a more immediate revenue stream compared to drug development, with growth expected over the next 1-3 years.
- Leveraging Nanotechnology for Enhanced Product Efficacy: The application of nanotechnology in products like NanoStilbene and Nano Cannabidiol provides a distinct competitive advantage and a significant growth opportunity. Nanoparticle formulations can improve bioavailability, targeted delivery, and overall efficacy of active ingredients, potentially leading to superior product performance compared to conventional supplements. This technological edge can differentiate TSOI's products in the market, appealing to consumers seeking advanced, science-backed solutions. Further research and development into new nano-formulations across its product lines could open new market segments and enhance existing product appeal, driving growth over the medium term (2-5 years).
- Monetization of Intellectual Property Portfolio: Therapeutic Solutions International, Inc.'s intellectual property portfolio, which includes the patented QuadraMune and cellular therapy technologies, is a crucial asset. This IP provides a barrier to entry for competitors and forms the foundation for future product development and potential licensing agreements. As the company progresses its advanced therapeutic candidates, the strength of its patents will be vital for protecting market exclusivity. Strategic licensing of its technologies or formulations to larger pharmaceutical partners could generate significant non-dilutive revenue, providing capital for further research and development. This long-term opportunity underpins the company's potential for sustained innovation and market presence.
What Are TSOI's Competitive Advantages?
- Proprietary and patented formulation of QuadraMune, a synergistic blend for immune modulation.
- Diverse intellectual property portfolio, including cellular therapy technologies, providing a competitive barrier.
- Specialized focus on immune system modulation for a broad range of complex and serious conditions.
- Application of nanotechnology in product development, potentially enhancing bioavailability and efficacy.
- Unique range of pterostilbene and cannabidiol formulations tailored for specific delivery methods and health targets.
What Does TSOI Do?
Therapeutic Solutions International, Inc., established in 2007 and headquartered in Elk City, Idaho, is a biotechnology firm singularly focused on the intricate science of modulating the immune system. The company's core mission is to develop and formulate immune-modulatory agents designed to address a diverse array of serious medical conditions. These targets include various forms of cancers, complex neurological disorders such as schizophrenia, suicidal ideation, traumatic brain injury (TBI), and chronic traumatic encephalopathy (CTE), alongside significant lung pathologies and general health maintenance. TSOI's product portfolio is bifurcated into advanced therapeutics in development and a robust line of nutraceuticals. Its flagship product, QuadraMune, stands as a patented, synergistic blend of four key compounds: pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. This unique formulation is specifically engineered to amplify natural killer cell activity within the immune system and to foster healthy cytokine production, crucial for immune balance. Beyond QuadraMune, the company offers a comprehensive suite of nutraceuticals. These include ProJuvenol, an anti-aging capsule blend designed for cellular rejuvenation. The company also leverages pterostilbene in various specialized formulations, such as NanoStilbene, a nanoemulsion for enhanced absorption; DermalStilbene, a topical spray; IsoStilbene, an injectable form; and NeuroStilbene, an intranasal version targeting neurological pathways. Further expanding its nutraceutical offerings, TSOI provides Nano Cannabidiol, a nanoparticle cannabidiol, and its composite product, NanoPlus, which integrates NanoStilbene. Specialized blends like NanoPSA, combining NanoStilbene with broccoli sprout extract, and the NLRP3 Trifecta, a two-product system featuring NanoPSA and GTE-50 green tea extract, underscore the company's innovative approach to health supplements. Concurrently, Therapeutic Solutions International, Inc. is actively engaged in the research and development of advanced therapeutics, specifically targeting the challenging areas of chronic traumatic encephalopathy, traumatic brain injury, and various lung diseases, aiming to bring novel solutions to these significant unmet medical needs.
What Products and Services Does TSOI Offer?
- Develops immune-modulatory agents to address serious conditions like cancers, neurological disorders, and lung pathologies.
- Formulates and sells QuadraMune, a patented blend designed to amplify natural killer cell activity and foster healthy cytokine production.
- Offers a diverse range of nutraceuticals, including anti-aging blends and specialized pterostilbene formulations.
- Provides nanotechnology-enhanced products such as NanoStilbene and Nano Cannabidiol for improved delivery and efficacy.
- Actively researches and develops advanced therapeutics for chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI).
- Engages in the development of novel treatments for various lung diseases.
- Focuses on general health maintenance through its immune-modulatory and nutraceutical products.
How Does TSOI Make Money?
- Generates revenue through the direct sale of its patented immune-modulatory nutraceutical, QuadraMune.
- Sells a comprehensive portfolio of specialized nutraceutical blends and formulations, targeting various health and wellness needs.
- Aims for future revenue streams from the successful development, licensing, or commercialization of its advanced therapeutic candidates for chronic traumatic encephalopathy, traumatic brain injury, and lung diseases.
What Industry Does TSOI Operate In?
Operating within the dynamic Healthcare sector, specifically the Biotechnology industry, Therapeutic Solutions International, Inc. positions itself as a developer of immune-modulatory agents. The biotechnology industry is characterized by intense research and development, high regulatory hurdles, and significant capital requirements, particularly for companies pursuing advanced therapeutics for complex diseases. TSOI's dual approach, combining patented nutraceuticals with a pipeline of advanced therapies for conditions like chronic traumatic encephalopathy, traumatic brain injury, and lung diseases, places it in a niche addressing both wellness and critical medical needs. Market trends indicate a growing demand for immune-boosting products and novel treatments for neurodegenerative and inflammatory conditions. The competitive landscape includes established pharmaceutical giants and numerous smaller biotech firms, all vying for market share in immune-oncology, neurology, and respiratory medicine. TSOI distinguishes itself through its specific focus on immune modulation and its proprietary formulations, aiming to carve out a unique position by targeting specific mechanisms of action and leveraging nanotechnology for enhanced product delivery.
Who Are TSOI's Key Customers?
- Individuals seeking to enhance or support their immune system function.
- Consumers interested in anti-aging and general health maintenance products.
- Patients and caregivers exploring complementary health solutions for conditions like cancers, neurological disorders, and lung pathologies.
- Health-conscious individuals seeking advanced, science-backed nutraceuticals, including those utilizing nanotechnology.
Therapeutic Solutions International, Inc. (TSOI) Valuation Context
Relative to its peer group, TSOI's quantitative score of 54/100 is below the peer average of 76/100.
TSOI Revenue & Earnings Trend
In Q3 2024, TSOI generated $20K in top-line revenue, marking a sequential decrease of 1.7%. The company recorded a net loss of $1.0M, with diluted EPS of $-0.00. Revenue has contracted over three consecutive quarters, which investors in this unknown Healthcare stock should monitor closely.
Company Profile
Therapeutic Solutions International, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Elk City, US. The company is led by CEO Timothy George Dixon. TSOI has traded publicly since 2008.
Key Financial Metrics
Return on assets is -65.9%, showing how much profit it generates from its asset base. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Therapeutic Solutions International, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -12.03 places it in the distress zone, a signal of elevated financial risk.
Insider Activity
The most recent 12 insider filings for Therapeutic Solutions International, Inc. break down as 0 sales and 12 purchases. On net that is roughly 255.9M shares acquired (about $201K) — insiders putting money in tends to read as conviction.
TSOI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in TSOI's future prospects, reflecting a positive outlook from those closest to the company.
- Community sentiment has shifted favorably, with discussions highlighting the potential impact of ongoing clinical trials on the company's growth.
- Innovations in therapeutic solutions have garnered attention, positioning TSOI as a key player in a rapidly evolving market.
- Market perception is improving as TSOI showcases its advancements in treatments, attracting interest from both investors and healthcare professionals.
Bear Case
- Concerns around the competitive landscape persist, with other companies in the sector making significant strides that could overshadow TSOI's advancements.
- Some community members express skepticism about the timelines for clinical trial results, which could delay potential revenue streams.
- Recent regulatory hurdles have raised questions about the approval process for TSOI's products, impacting investor confidence.
- Market volatility and broader economic concerns may lead to cautious sentiment towards speculative stocks like TSOI, affecting its attractiveness.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $19,667 | -$1M | -$0.0002 |
| Q2 2024 | $20,005 | -$390,046 | -$0.0001 |
| Q1 2024 | $21,814 | -$585,141 | -$0.0001 |
Based on FMP financials and quantitative analysis
TSOI Latest News
No recent news available for TSOI.
TSOI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TSOI.
Price Targets
Wall Street price target analysis for TSOI.
TSOI MoonshotScore
What does this score mean?
The MoonshotScore rates TSOI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Timothy George Dixon
Unknown
Timothy George Dixon serves as the leader of Therapeutic Solutions International, Inc., overseeing a small team of three employees dedicated to advancing immune-modulatory therapies. While specific details regarding his prior career history, educational background, or previous roles are not provided in the available data, his current position indicates a leadership role in the biotechnology sector. His responsibilities encompass guiding the company's strategic direction, particularly in the development of both its nutraceutical lines and its pipeline of advanced therapeutics targeting complex diseases.
Track Record: Under Timothy George Dixon's leadership, Therapeutic Solutions International, Inc. has continued its focus on immune modulation, maintaining a portfolio that includes the patented QuadraMune and a range of specialized nutraceuticals. Key strategic decisions have involved the ongoing development of advanced therapeutics for chronic traumatic encephalopathy, traumatic brain injury, and lung diseases. His tenure is marked by the company's commitment to leveraging intellectual property, including cellular therapy technologies, to address significant unmet medical needs within the healthcare landscape.
TSOI OTC Market Information
Therapeutic Solutions International, Inc. (TSOI) trades on the OTC market under the "OTC Other" tier. This designation is for companies that do not qualify for OTCQX or OTCQB, the higher tiers of the OTC Markets. Companies in the "OTC Other" tier typically have limited public disclosure requirements, often providing less financial and operational information compared to companies listed on major exchanges like NYSE or NASDAQ. This tier is associated with higher risk due to a lack of transparency and often signifies companies that do not meet the financial or governance standards required for more regulated markets.
- OTC Tier: OTC Other
- Limited public information and unknown disclosure status can hinder informed investment decisions.
- High price volatility and wide bid-ask spreads due to limited liquidity on the OTC Other market.
- Difficulty in exiting positions quickly or at favorable prices, posing a significant investment risk.
- Increased susceptibility to market manipulation due to less stringent regulatory oversight compared to major exchanges.
- Limited or no analyst coverage, making it harder to find independent research and valuation.
- Verify the availability and recency of any financial statements or public disclosures.
- Investigate the background and track record of management beyond the provided summary.
- Assess the progress and scientific validity of the product pipeline, especially advanced therapeutics.
- Thoroughly understand the intellectual property portfolio and its protection.
- Evaluate the market potential and competitive landscape for both nutraceuticals and therapeutic candidates.
- Research any past regulatory actions or compliance issues.
- Understand the company's financing history and future capital requirements.
- Active development of advanced therapeutics targeting serious conditions like CTE, TBI, and lung diseases.
- Possession of patented products, such as QuadraMune, indicating proprietary technology.
- Stated focus on immune system modulation, a recognized area of scientific research.
- Mention of intellectual property surrounding cellular therapy technologies.
- A defined product portfolio, including a range of specialized nutraceuticals.
What Investors Ask About Therapeutic Solutions International, Inc. (TSOI) — Healthcare
What does the AI Score mean for TSOI?
TSOI holds an AI Score of 54/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Therapeutic Solutions International, Inc. (TSOI) specializes in immune system modulation, developing agents for diverse serious conditions including cancers, neurological disorders, and lung …
What does Therapeutic Solutions International, Inc. do?
Therapeutic Solutions International, Inc. (TSOI) is a biotechnology company focused on modulating the immune system to address a wide spectrum of serious health conditions. The company's operations encompass two primary areas: the development of advanced therapeutics and the provision of specialized nutraceuticals.
What are the key growth opportunities for TSOI in healthcare?
Therapeutic Solutions International, Inc. has several key growth opportunities within the healthcare sector. A primary driver is the ongoing development of advanced therapeutics for conditions with significant unmet medical needs, such as chronic traumatic encephalopathy, traumatic brain injury, and various lung diseases. Successful progression and commercialization of these therapies could unlock substantial market value.
What are the main risks for TSOI, particularly as an OTC company?
Therapeutic Solutions International, Inc. faces several significant risks, exacerbated by its listing on the OTC Other market. Financially, the company currently operates with a substantial negative profit margin of -2191.9%, indicating ongoing unprofitability. As an OTC Other company, TSOI is subject to limited liquidity, which can lead to wide bid-ask spreads and difficulty in trading shares or exiting positions.
How does Therapeutic Solutions International, Inc. position itself in the competitive biotechnology industry?
Therapeutic Solutions International, Inc. positions itself in the competitive biotechnology industry by focusing on a specialized niche: immune system modulation for a diverse array of serious conditions. Unlike many biotech firms that might specialize in a single disease area, TSOI targets a broad spectrum, from cancers to neurological and lung pathologies, through a dual approach.
What are the key factors to evaluate for TSOI?
Therapeutic Solutions International, Inc. (TSOI) holds an AI score of 54/100 (moderate). (TSOI) operates within the biotechnology sector, focusing on immune system modulation to address a broad spectrum of serious conditions, from cancers to neurological disorders and lung pathologies. Not financial advice.
How frequently does TSOI data refresh on this page?
TSOI's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TSOI's recent stock price performance?
Therapeutic Solutions International, Inc. (TSOI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Patented QuadraMune formulation with a specific immune-modulatory mechanism. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TSOI overvalued or undervalued right now?
Therapeutic Solutions International, Inc. (TSOI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based solely on provided source data. No external research was conducted.